Valeant Pharmaceuticals Intl Inc (VRX) Receives C$22.50 Average PT from Analysts
Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) has earned an average recommendation of “Hold” from the five brokerages that are presently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is C$22.50.
VRX has been the topic of several research reports. TD Securities upped their price objective on shares of Valeant Pharmaceuticals Intl to C$26.00 and gave the company a “hold” rating in a report on Wednesday, July 12th. Royal Bank Of Canada decreased their price objective on shares of Valeant Pharmaceuticals Intl to C$22.50 and set a “sector perform” rating on the stock in a report on Friday, October 20th.
In related news, Director John Paulson sold 24,700 shares of the company’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of C$14.66, for a total value of C$362,102.00. Also, Director Schutter Richard Urbain De purchased 4,900 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The stock was acquired at an average price of C$14.35 per share, for a total transaction of C$70,315.00.
Valeant Pharmaceuticals Intl (TSE VRX) traded down C$0.61 during trading hours on Monday, hitting C$14.73. 1,996,700 shares of the company’s stock traded hands, compared to its average volume of 1,180,000. Valeant Pharmaceuticals Intl has a 12-month low of C$11.20 and a 12-month high of C$28.40.
TRADEMARK VIOLATION WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/11/04/valeant-pharmaceuticals-intl-inc-vrx-receives-c22-50-average-pt-from-analysts.html.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.